IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Integris Medtech IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ [●] Cr. The company is based in New Delhi and caters to Pharmaceutical sector. Axis Capital , Citigroup Global Markets India , ICICI Securities , IIFL Securities are the merchant bankers of Integris Medtech IPO. It is a MainBoard Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 9th October 2025.
Integris Medtech IPO posted revenues of ₹ 1,941.00 Cr. and PAT of ₹ 1,070.28 Cr. in FY26 on annualised basis.
Revenue:
₹ 1,941.00 Cr.
EBITDA Margin:
16.22
% 
Net Worth: ₹ 2303.45 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Financial results of Integris Medtech IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Jun-25 | FY25 | FY24 | FY23 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 4019.62 | 3641.33 | 2989.20 | 2553.87 | |
| Net Worth | 2303.45 | 1153.74 | 1138.42 | 1075.82 | |
| Total Debt | 793.42 | 1729.46 | 813.11 | 556.53 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
485.25
1,941.00 |
1902.47 | 1553.38 | 1348.10 | |
EBITDA
EBITDA on annualised basis |
78.73
314.92 |
309.40 | 190.45 | 168.82 | |
PAT
PAT on annualised basis |
267.57
1,070.28 |
70.68 | -4.88 | -40.54 | |
Integris Medtech IPO PAT Margin is 55.14 % , ROCE (Return on Capital Employed) is 4.23 % as per latest financial. The below table shows Integris Medtech IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Jun-25 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| EBITDA Margin (%) | 16.22 | 16.26 | 12.26 | 12.52 |
| PAT Margin (%) | 55.14 | 3.72 | -0.31 | -3.01 |
| EPS (₹) | 28.00 | 5.82 | -1.38 | -5.99 |
| ROE (%) | 11.62 | 6.13 | -0.43 | -3.77 |
| ROCE (%) | 4.23 | 14.51 | 8.33 | 9.41 |
| ROA (%) | 6.66 | 1.94 | -0.16 | -1.59 |
| Debt to Equity | 0.34 | 1.50 | 0.71 | 0.52 |
The market Capitalisation of Integris Medtech IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Integris Medtech IPO prospectus highlights an Return on Equity (ROE) of 11.62 % , Return on Assets (ROA) of 6.66 %, and an EBITDA Margin of 16.22 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Integris Medtech IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Integris Medtech IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Integris Medtech IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Integris Medtech IPO reported revenue of ₹ 1941.00 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Integris Medtech IPO provide insights into sales growth, market demand, and business scalability.
Integris Medtech recorded an EBITDA of ₹ 314.92 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Integris Medtech Profit After Tax (PAT) is ₹ 1,070.28 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 1,941.00 Cr.
EBITDA Margin:
16.22
%
Net Worth: ₹ 2,303.45 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA:
[●]
Integris Medtech operates in Pharmaceutical and Offers Diversified Medical Products And Laboratory Solutions Company. The Issue is listed on BSE,NSE in Oct, 2025. Integris Medtech IPO size was with Issue price of .
Merchant Banker(s) of Integris Medtech IPO: Axis Capital Limited , Citigroup Global Markets India Private Limited , ICICI Securities Limited , IIFL Securities Limited
Integris Medtech IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Integris Medtech IPO listed at a listing price of against the offer price of .
The current market price of Integris Medtech is .
Why Us?
